FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111510880> ?p ?o ?g. }

• W2111510880 endingPage "360" @default.
• W2111510880 startingPage "355" @default.
• W2111510880 abstract "Annals of the New York Academy of SciencesVolume 761, Issue 1 p. 355-360 Raloxifene is a Tissue-Selective Agonist/Antagonist That Functions through the Estrogen Receptor R. FUCHS-YOUNG, Corresponding Author R. FUCHS-YOUNG Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Corresponding authour.Search for more papers by this authorA. L. GLASEBROOK, A. L. GLASEBROOK Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorL. L. SHORT, L. L. SHORT Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorM. W. DRAPER, M. W. DRAPER Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorM. K. RIPPY, M. K. RIPPY Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorH. W. COLE, H. W. COLE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorD. E. MAGEE, D. E. MAGEE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorJ. D. TERMINE, J. D. TERMINE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorH. U. BRYANT, H. U. BRYANT Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this author R. FUCHS-YOUNG, Corresponding Author R. FUCHS-YOUNG Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Corresponding authour.Search for more papers by this authorA. L. GLASEBROOK, A. L. GLASEBROOK Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorL. L. SHORT, L. L. SHORT Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorM. W. DRAPER, M. W. DRAPER Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorM. K. RIPPY, M. K. RIPPY Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorH. W. COLE, H. W. COLE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorD. E. MAGEE, D. E. MAGEE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorJ. D. TERMINE, J. D. TERMINE Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this authorH. U. BRYANT, H. U. BRYANT Skeletal Disease Research Endocrine Division Lilly Research Laboratories Eli Lilly and Co. Indianapolis, Indiana 46285.Search for more papers by this author First published: June 1995 https://doi.org/10.1111/j.1749-6632.1995.tb31392.xCitations: 55AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Glasebrook, A. L. et al. 1993. Multiple binding sites for the anti-estrogen raloxifene. J. Bone Miner. Res. 8 (Suppl.): S268. 2 Yang, N. et al. 1994. TGF-B3: a target for estrogen and anti-estrogens in inhibiting bone resorption. Submitted for publication. 3 Yang, N. et al. 1994. Estrogen receptor: one transcription factor, two genomic pathways. Submitted for publication. 4 Black, L. et al. 1994. Raloxifene prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy. J. Clin. Invest. 93: 63– 69. 5 Thompson, E. et al. 1988. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 48: 6764– 6768. 6 Clemens, J. et al. 1983. Effects of a new antiestrogen, keoxifene (LY156759), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32: 2869– 2875. 7 Draper, M. et al. 1994. Effects of raloxifene HCl on serum markers of bone and lipid metabolism-dose response relationships. Calcif. Tissue Int. 4: 339. 8 Draper, M. et al. 1993. Effects of raloxifene on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. In Proceedings 1993. Fourth International Symposium on Osteoporosis and Consensus Development Conference. C. Christiansen & B. Riis, Eds. 119– 121. Handelstrykkeriet Aalborg ApS. Aalborg , Denmark . Citing Literature Volume761, Issue1Steroid Receptors and AntihormonesJune 1995Pages 355-360 ReferencesRelatedInformation" @default.
• W2111510880 created "2016-06-24" @default.
• W2111510880 creator A5007257386 @default.
• W2111510880 creator A5016358291 @default.
• W2111510880 creator A5023478435 @default.
• W2111510880 creator A5032362159 @default.
• W2111510880 creator A5032923464 @default.
• W2111510880 creator A5042761913 @default.
• W2111510880 creator A5043253865 @default.
• W2111510880 creator A5084382911 @default.
• W2111510880 creator A5085077525 @default.
• W2111510880 date "1995-06-01" @default.
• W2111510880 modified "2023-10-18" @default.
• W2111510880 title "Raloxifene is a Tissue-Selective Agonist/Antagonist That Functions through the Estrogen Receptor" @default.
• W2111510880 cites W2007007521 @default.
• W2111510880 cites W2008039212 @default.
• W2111510880 doi "https://doi.org/10.1111/j.1749-6632.1995.tb31392.x" @default.
• W2111510880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7625735" @default.
• W2111510880 hasPublicationYear "1995" @default.
• W2111510880 type Work @default.
• W2111510880 sameAs 2111510880 @default.
• W2111510880 citedByCount "77" @default.
• W2111510880 countsByYear W21115108802012 @default.
• W2111510880 countsByYear W21115108802014 @default.
• W2111510880 countsByYear W21115108802015 @default.
• W2111510880 countsByYear W21115108802016 @default.
• W2111510880 countsByYear W21115108802017 @default.
• W2111510880 countsByYear W21115108802018 @default.
• W2111510880 countsByYear W21115108802021 @default.
• W2111510880 countsByYear W21115108802022 @default.
• W2111510880 crossrefType "journal-article" @default.
• W2111510880 hasAuthorship W2111510880A5007257386 @default.
• W2111510880 hasAuthorship W2111510880A5016358291 @default.
• W2111510880 hasAuthorship W2111510880A5023478435 @default.
• W2111510880 hasAuthorship W2111510880A5032362159 @default.
• W2111510880 hasAuthorship W2111510880A5032923464 @default.
• W2111510880 hasAuthorship W2111510880A5042761913 @default.
• W2111510880 hasAuthorship W2111510880A5043253865 @default.
• W2111510880 hasAuthorship W2111510880A5084382911 @default.
• W2111510880 hasAuthorship W2111510880A5085077525 @default.
• W2111510880 hasConcept C121608353 @default.
• W2111510880 hasConcept C126322002 @default.
• W2111510880 hasConcept C161191863 @default.
• W2111510880 hasConcept C2779889926 @default.
• W2111510880 hasConcept C41008148 @default.
• W2111510880 hasConcept C530470458 @default.
• W2111510880 hasConcept C71924100 @default.
• W2111510880 hasConcept C84606932 @default.
• W2111510880 hasConceptScore W2111510880C121608353 @default.
• W2111510880 hasConceptScore W2111510880C126322002 @default.
• W2111510880 hasConceptScore W2111510880C161191863 @default.
• W2111510880 hasConceptScore W2111510880C2779889926 @default.
• W2111510880 hasConceptScore W2111510880C41008148 @default.
• W2111510880 hasConceptScore W2111510880C530470458 @default.
• W2111510880 hasConceptScore W2111510880C71924100 @default.
• W2111510880 hasConceptScore W2111510880C84606932 @default.
• W2111510880 hasIssue "1" @default.
• W2111510880 hasLocation W21115108801 @default.
• W2111510880 hasLocation W21115108802 @default.
• W2111510880 hasOpenAccess W2111510880 @default.
• W2111510880 hasPrimaryLocation W21115108801 @default.
• W2111510880 hasRelatedWork W1506200166 @default.
• W2111510880 hasRelatedWork W1995515455 @default.
• W2111510880 hasRelatedWork W2059554179 @default.
• W2111510880 hasRelatedWork W2080531066 @default.
• W2111510880 hasRelatedWork W2748952813 @default.
• W2111510880 hasRelatedWork W2899084033 @default.
• W2111510880 hasRelatedWork W3031052312 @default.
• W2111510880 hasRelatedWork W3032375762 @default.
• W2111510880 hasRelatedWork W3108674512 @default.
• W2111510880 hasRelatedWork W4249369074 @default.
• W2111510880 hasVolume "761" @default.
• W2111510880 isParatext "false" @default.
• W2111510880 isRetracted "false" @default.
• W2111510880 magId "2111510880" @default.
• W2111510880 workType "article" @default.